Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications | Journal of Experimental & Clinical Cancer Research | Full Text

Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications | Journal of Experimental & Clinical Cancer Research | Full Text

Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications

New therapies are urgently needed in melanoma particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors.

Authors:Wei Liu, Paweł Stachura, Haifeng C. Xu, Nikkitha Umesh Ganesh, Fiona Cox, Ruifeng Wang, Karl S. Lang, Jay Gopalakrishnan, Dieter Häussinger, Bernhard Homey, Philipp A. Lang and Aleksandra A. Pandyra

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:38

Content type:Research

Published on: 21 February 2020

• ViewFull Text
 
• ViewPDF